ORGANOGENESIS HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.35 USD | +2.84% |
|
-18.97% | -42.54% |
| 29/02 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 | |
| 29/02 | Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 455M 37.92B | Sales 2025 * | 490M 40.89B | Capitalization | 310M 25.86B |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -167M | Net income 2025 * | 8M 667M | EV / Sales 2024 * | 0.65 x |
| Net cash position 2024 * | 15.31M 1.28B | Net cash position 2025 * | 14.68M 1.22B | EV / Sales 2025 * | 0.6 x |
| P/E ratio 2024 * |
-176
x | P/E ratio 2025 * |
24.7
x | Employees | 862 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Organogenesis Holdings Inc.
More recommendations
More press releases
| 1 day | +2.84% | ||
| 1 week | -18.97% | ||
| Current month | -17.25% | ||
| 1 month | -14.86% | ||
| 3 months | -33.05% | ||
| 6 months | +9.30% | ||
| Current year | -42.54% |
1 week
2.17
3.07
1 month
2.173.07
Current year
2.174.71
1 year
1.884.71
3 years
1.8023.99
5 years
1.8024.34
10 years
1.80310.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gary Gillheeney
CEO | Chief Executive Officer | 69 | 01/14/01 |
David Francisco
DFI | Director of Finance/CFO | 59 | 16/21/16 |
Patrick Bilbo
COO | Chief Operating Officer | 63 | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Glenn Nussdorf
BRD | Director/Board Member | 70 | 01/03/01 |
Alan Ades
BRD | Director/Board Member | 86 | 01/03/01 |
Michael Driscoll
BRD | Director/Board Member | 63 | 15/22/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 27 M€ | -5.03% | - | |
| 0.09% | 29 M€ | -4.33% | ||
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2.35 | +2.84% | 903,642 |
| 25/24/25 | 2.285 | -23.32% | 2,555,483 |
| 24/24/24 | 2.98 | 0.00% | 2,973,406 |
| 23/24/23 | 2.98 | +0.34% | 631,653 |
| 22/24/22 | 2.97 | +2.41% | 1,737,377 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.
Calendar
10/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.35
USD
Average target price
4.833
USD
Spread / Average Target
+105.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.54% | 310M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ORGO Stock
